Decisional Capacity and Informed Consent in Fragile X Syndrome
NCT02465931 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152
Last updated 2019-03-07
Summary
The Decisional Capacity and Informed Consent in Fragile X Syndrome (FXS) project is for the Eunice Kennedy Shriver National Institute of Child Health \& Human Development, 1R01HD071987-01A1, and will provide the first comprehensive description of decisional capacity of individuals with FXS; identify individual, family, and experiential factors associated with variability in decisional capacity; determine the validity of caregiver and expert ratings; and develop evidence-based guidelines for categorizing decisional capacity of individuals with FXS. The researchers will develop a methodologically rigorous and conceptually grounded decision aid using digital technology to enhance participation of individuals with FXS in the consent process.
Conditions
- Fragile X Syndrome (FXS)
Interventions
- OTHER
-
Paper and Pencil Informed Consent
Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
- OTHER
-
Digital Informed Consent Tool
Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
Sponsors & Collaborators
-
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
collaborator NIH -
RTI International
lead OTHER
Principal Investigators
-
Robert Furberg, PhD · RTI International
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SCREENING
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Max Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-14
- Primary Completion
- 2017-03-21
- Completion
- 2017-03-21
Countries
- United States
Study Locations
More Related Trials
-
Cognitive Training for Fragile X Syndrome
NCT02747394 ·Status: COMPLETED ·Phase: NA
-
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
NCT05418049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Trial of Metformin in Individuals With Fragile X Syndrome
NCT03479476 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
NCT01325740 ·Status: SUSPENDED ·Phase: PHASE2
-
Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
NCT00823368 ·Status: COMPLETED
-
An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
NCT05832255 ·Status: SUSPENDED ·Phase: PHASE2
-
Phase 1/2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients With FOXG1 Syndrome (FS)
NCT07293546 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome
NCT01144741 ·Status: TERMINATED
-
Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome
NCT01357239 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)
NCT01482143 ·Status: COMPLETED ·Phase: PHASE1
-
Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia
NCT06560346 ·Status: WITHDRAWN
-
Novel Clinical Target in Fragile X Syndrome
NCT04314856 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of Acamprosate in Fragile x Syndrome
NCT01911455 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
NCT03614663 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
NCT05302271 ·Status: RECRUITING ·Phase: PHASE1
-
Metformin in Children and Adults With Fragile X Syndrome
NCT03722290 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
NCT03802799 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID
NCT00006335 ·Status: COMPLETED
-
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
NCT01254045 ·Status: COMPLETED ·Phase: PHASE2
-
Measurement of Frataxin mRNA in Biofluids
NCT06496451 ·Status: COMPLETED
-
Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients
NCT00718341 ·Status: COMPLETED ·Phase: PHASE2
-
Facioscapulohumeral Dystrophy in Children
NCT02625662 ·Status: COMPLETED
-
An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
NCT01013480 ·Status: TERMINATED ·Phase: PHASE2
-
A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT03862950 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)
NCT01433354 ·Status: TERMINATED ·Phase: PHASE2/PHASE3